Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Daiichi Sankyo Co., Ltd: PharmaVitae Profile
Market Study
Published: June 2010
Pages: 63
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 3562.50 Buy Now!
Research from: Datamonitor
Sector: Corporate & Fiscal
Introduction
This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Daiichi Sankyo's performance against key rivals in the prescription pharmaceutical sector
*Assess the importance of Daiichi Sankyo's olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) to the company's outlook
*Evaluate the prospects of the company's recent acquisition, Ranbaxy
This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Daiichi Sankyo's performance against key rivals in the prescription pharmaceutical sector
*Assess the importance of Daiichi Sankyo's olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) to the company's outlook
*Evaluate the prospects of the company's recent acquisition, Ranbaxy